1. Home
  2. NEXT vs OCS Comparison

NEXT vs OCS Comparison

Compare NEXT & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NextDecade Corporation

NEXT

NextDecade Corporation

HOLD

Current Price

$5.26

Market Cap

1.6B

Sector

Energy

ML Signal

HOLD

Logo Oculis Holding AG Ordinary shares

OCS

Oculis Holding AG Ordinary shares

HOLD

Current Price

$26.75

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXT
OCS
Founded
2010
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NEXT
OCS
Price
$5.26
$26.75
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$9.00
$39.57
AVG Volume (30 Days)
3.0M
219.0K
Earning Date
02-27-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$991,999.00
Revenue This Year
N/A
$14.53
Revenue Next Year
N/A
$691.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.76
$14.00
52 Week High
$12.12
$27.43

Technical Indicators

Market Signals
Indicator
NEXT
OCS
Relative Strength Index (RSI) 49.30 80.02
Support Level $4.76 $22.60
Resistance Level $5.56 $27.43
Average True Range (ATR) 0.32 1.35
MACD 0.04 0.46
Stochastic Oscillator 62.89 90.92

Price Performance

Historical Comparison
NEXT
OCS

About NEXT NextDecade Corporation

NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Share on Social Networks: